Neuro-Oncology Nugget: Bivalent EGFR/IL13Rα2 CAR T Cells for Recurrent Glioblastoma
About this episode
Shahad Abdulsahib discusses a phase 1 clinical trial of bivalent EGFR and IL13Rα2 CAR T cells for treating recurrent glioblastoma.
Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular bivalent EGFR and IL13Rα2 CAR T cells for recurrent glioblastoma, published in Nature Medicine .
More episodes of Neuro-Oncology: The Podcast
- Neuro-Oncology Nugget: Career Development Outreach from SNO
- Neuro-onc Narratives: An Interview with Caroline Catlin
- Author Interview: "DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma"
- Hot Topics: AYA in Neuro-Oncology
- SNObound: Career Advice from Dr. Brooke Braman in Radiation Oncology
- Author Interview: Global analysis of clinical trials for children and adolescents with CNS tumors
Explore listener stats, chart rankings, contacts and more on the Neuro-Oncology: The Podcast podcast page.